Boditech Med KRX:206640KOSDAQ
바디텍메드 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked1since Sep 11
In Q2 2026, Boditech Med reported revenue of ₩50.4bn, up 21.5% year on year, and operating profit of ₩8.2bn. Boditech Med (바디텍메드) appeared in 0 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Sep 23 with 1 article.
Boditech Med quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩50.4bn | +21.5% | ₩8.2bn margin 16.3% | ₩7.6bn |
| Q1 2026 | ₩42.8bn | +9.6% | ₩6.8bn margin 15.9% | ₩9.5bn |
| Q4 2025 derived | ₩41.6bn | +33.1% | ₩5.1bn margin 12.2% | ₩1.4bn |
| Q3 2025 | ₩39.9bn | +6.3% | ₩6.6bn margin 16.5% | ₩7.8bn |
| Q2 2025 | ₩41.5bn | +14.4% | ₩9.2bn margin 22.2% | ₩7.5bn |
| Q1 2025 | ₩39.1bn | +18.1% | ₩8.1bn margin 20.7% | ₩7.3bn |
| Q4 2024 derived | ₩31.2bn | -10.6% | ₩2.2bn margin 6.9% | ₩4.8bn |
| Q3 2024 | ₩37.6bn | +7.8% | ₩8.8bn margin 23.5% | ₩6.1bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Boditech Med top stories 2 weeks, by number of outlets
- 1